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Prior treatment exposure in patients with relapsed/refractory multi-ple myeloma may affect outcomes with subsequent therapies. Weanalyzed efficacy and safety according to prior treatment in the
phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexam-
ethasone (ixazomib-Rd) versus placebo-Rd. Patients with relapsed/refrac-
tory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy
and safety were evaluated in subgroups defined according to type (pro-
teasome inhibitor [PI] and immunomodulatory drug) and number (1 vs.
2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had
received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425
patients had received 1 prior therapy, and 297 received 2 or 3 prior ther-
apies. At a median follow up of ~15 months, PFS was prolonged with
ixazomib-Rd vs. placebo-Rd regardless of type of prior therapy received;
HR 0.739 and 0.749 in PI-exposed and –naïve patients, HR 0.744 and
0.700 in immunomodulatory-drug-exposed and -naïve patients, respec-
tively. PFS benefit with ixazomib-Rd vs. placebo-Rd appeared greater in
patients with 2 or 3 prior therapies (HR 0.58) and in those with 1 prior
therapy without prior transplant (HR 0.60) versus those with 1 prior ther-
apy and transplant (HR 1.23). Across all subgroups, toxicity was consis-
tent with that seen in the intent-to-treat population. In patients with
relapsed/refractory multiple myeloma, ixazomib-Rd was associated with
a consistent clinical benefit vs. placebo-Rd regardless of prior treatment
with bortezomib or immunomodulatory drugs. Patients with 2 or 3 prior
therapies, or 1 prior therapy without transplant seemed to have greater
benefit than patients with 1 prior therapy and transplant.  
TOURMALINE-MM1 registered at clinicaltrials.gov identifier: 01564537. 
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ABSTRACT
Introduction 
Novel agents such as proteasome inhibitors (PIs) and immunomodulatory drugs
have revolutionized multiple myeloma (MM) treatment, with significant improve-
ments in overall survival (OS) evident over the past 15 years.1-5 Despite the use of
these novel agents, MM follows a relapsing course, with
many patients receiving multiple lines of therapy and ulti-
mately becoming refractory to some agents,6 possibly due
to the development and selection of increasingly treat-
ment-resistant clones.7 Long-term outcomes, including
progression-free survival (PFS) and OS, also become pro-
gressively shorter with increasing number of prior thera-
pies,6,8-11 as rates of medical comorbidities and complica-
tions increase.12 Prior therapies are therefore often consid-
ered when selecting a therapy at relapse, with prior thera-
pies shown to affect the outcomes of subsequent lines of
treatment. For example, outcomes for thalidomide-
exposed patients have been shown to be worse than for
thalidomide-naïve patients following 
treatment with bortezomib12 and with lenalidomide-dex-
amethasone.13 
Until 2012, bortezomib was the only PI available so sub-
sequent treatment with other drugs of the same class was
not possible outside of a clinical trial. However, retreat-
ment with bortezomib has been shown to be effective14-17
and, following the introduction of carfilzomib, the feasi-
bility of retreatment with a different agent of the same
class and with a similar mechanism of action has been
demonstrated.17 Similarly, for the immunomodulatory
drugs, lenalidomide plus dexamethasone improved
responses, time to progression (TTP), and PFS compared
with dexamethasone alone in patients with or without
prior thalidomide exposure.13 
The phase 3, randomized, placebo-controlled, double-
blind TOURMALINE-MM1 study in 722 patients with
relapsed/refractory MM (RRMM) demonstrated a signifi-
cant 35% improvement in PFS with the all-oral combina-
tion of ixazomib plus lenalidomide-dexamethasone (Rd)
compared with placebo-Rd (median PFS 20.6 vs. 14.7
months; hazard ratio 0.74; P=0.01).18 On the basis of these
data, ixazomib, in combination with lenalidomide and
dexamethasone (ixazomib-Rd), was approved in 2015 by
the US Food and Drug Administration, and in 2016 by the
European Medicines Agency, for the treatment of patients
with MM who have received at least one prior line of ther-
apy. Given the widespread use of PIs and immunomodu-
latory drugs as first-line therapy, it is important to deter-
mine their impact on the overall and relative efficacy of
new agents for the treatment of RRMM. The TOURMA-
LINE-MM1 study included patients with prior exposure to
PIs and the immunomodulatory drugs thalidomide and
lenalidomide, and patients with and without prior trans-
plant. Here we present a subgroup analysis of efficacy and
safety data for ixazomib-Rd compared with placebo-Rd
according to the number and type of prior therapies
received.
Methods 
Study design and participants
Adult patients with measurable relapsed, refractory, or relapsed
and refractory MM who had received 1-3 prior lines of therapy
were eligible. Full eligibility criteria have been reported
previously.18 Patients who had received prior PI- and
thalidomide/lenalidomide (thal/R)-based regimens were eligible,
as were primary refractory patients and patients refractory to
thalidomide; patients who were refractory to prior PI- or lenalido-
mide-based therapy were not eligible. Study endpoints have been
reported previously.18 The primary endpoint was PFS as assessed
by a blinded independent review committee (IRC). The study was
performed in accordance with the International Conference on
Harmonisation Good Clinical Practice guidelines and appropriate
regulatory requirements, and with approval of Institutional
Review Boards at individual enrolling institutions. All patients pro-
vided written informed consent.  A total of 722 patients were ran-
domized 1:1 to receive oral ixazomib 4 mg (ixazomib-Rd arm,
N=360) or placebo (placebo-Rd arm, N=362) on days 1, 8, and 15
of 28-day cycles, with oral lenalidomide 25 mg on days 1–21 and
oral dexamethasone 40 mg on days 1, 8, 15 and 22, until disease
progression or unacceptable toxicity. Stratification factors were
number of prior therapies per investigator assessment (1 vs. 2 or 3),
International Staging System disease stage (I or II vs. III), and prior
PI exposure (yes vs. no); patients were not stratified by prior thal/R
exposure or thalidomide-refractoriness. A prior line of therapy
was defined as 1 or more cycles of a planned treatment program,
as determined by the investigator. Overall patient baseline demo-
graphics and disease characteristics were well balanced between
ixazomib-Rd and placebo-Rd arms.18
Responses were assessed per International Myeloma Working
Group 2011 criteria19 every cycle until disease progression, using a
central laboratory. Adverse events (AEs) were assessed per
National Cancer Institute’s Common Terminology Criteria for
Adverse Events version 4.03 during treatment and until 30 days
after the last dose of study medication was administered. 
Analyses by prior treatment exposure
Subgroup analyses were performed for efficacy and safety out-
comes relative to type of prior regimen. Patient subgroups were
defined according to prior exposure to the PIs bortezomib and
carfilzomib, and the immunomodulatory drugs lenalidomide and
thalidomide. Outcomes were also assessed according to number
of prior lines of therapy (1 vs. 2/3, per study stratification) and,
within those subgroups, according to components of prior thera-
pies, including transplant.
Statistical analysis
At a pre-planned analysis (median follow up of ~15 months),
the study met the primary endpoint of a significant PFS benefit
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Table 1. Number and type of prior therapies received by patients in
TOURMALINE-MM1.
Ixazomib-Rd Placebo-Rd
(N=360) (N=362) 
Number of prior therapies, n (%)
1 212 (59) 213 (59)
2–3 148 (41) 149 (41)
Prior therapy type, n (%)
PI naïve 110 (31) 109 (30) 
Bortezomib naïve 112 (31) 112 (31) 
PI exposed 250 (69) 253 (70) 
Bortezomib exposed 248 (69) 250 (69) 
Carfilzomib exposed 1 (<1) 4 (1)
Immunomodulatory drug naïve 167 (46) 158 (44) 
Thalidomide naïve 203 (56) 192 (53) 
Lenalidomide naïve 316 (88) 318 (88) 
Immunomodulatory drug exposed 193 (54) 204 (56) 
Thalidomide exposed 157 (44) 170 (47) 
Lenalidomide exposed 44 (12) 44 (12) 
Thalidomide refractory 40 (11) 49 (14) 
PI: proteasome inhibitor; Rd: lenalidomide-dexamethasone.
with ixazomib-Rd vs. placebo-Rd. Consistent with the statistical
methodology, this was therefore the final statistical analysis for
PFS. Per protocol, the study continued in a double-blind, placebo-
controlled manner to gain more mature OS data; a second pre-
planned analysis (median follow up of ~23 months) was conduct-
ed for safety and survival.  Time-to-event distributions were esti-
mated using Kaplan-Meier methodology, with stratified log-rank
tests and Cox models (alpha=0.05, two-sided) used for compar-
isons of time-to-event endpoints. A stratified Cochran-Mantel-
Haenszel c2 test was used to assess inter-arm differences in
response rates. The subgroup analyses were not powered for for-
mal statistical testing.
Results
Patients
Of the 722 patients in the ITT population, 70% had
received a prior PI (250 [69%] in the ixazomib arm, and
253 [70%] in the placebo arm).  The majority of PI-
exposed patients had received bortezomib (1 patient in
the ixazomib arm and 4 patients in the placebo arm had
received prior carfilzomib). Over half (55%) had received
prior thalidomide or lenalidomide (193 [54%] in the ixa-
zomib arm and 204 [56%] in the placebo arm) (Table 1).
Of these, in the ixazomib and placebo arms, respectively,
157 (44%) and 170 (47%) patients had received prior
thalidomide, and 44 (12%) and 44 (12%) patients had
received prior lenalidomide; there was no prior pomalido-
mide therapy. A total of 425 patients had received 1 prior
therapy (212 in the ixazomib arm and 213 in the placebo
arm) and 297 had received 2 or 3 prior therapies (148 in
the ixazomib arm and 149 in the placebo arm).
Efficacy according to type of prior therapies received
At a median follow up of ~15 months (14.8 months in
the ixazomib-Rd group and 14.6 months in the placebo-
Rd group), there was a clinical benefit in terms of pro-
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Figure 1. Forest plot of progression-free survival (PFS) according to number and type of prior therapies (A), and forest plot of PFS according to type of prior therapy
in patients who have received 1 versus 2 or 3 prior therapies (B). CI: confidence interval; HR: hazard ratio; PI: proteasome inhibitor; Rd: lenalidomide-dexametha-
sone.
A
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longed PFS with ixazomib-Rd vs. placebo-Rd regardless of
prior therapy received (Figure 1A, Figure 2); median PFS
was 18.4 vs. 13.6 months (HR 0.74) in PI-exposed patients,
not reached vs. 15.7 months (HR 0.749) in PI-naïve
patients, not reached vs. 17.5 months (HR 0.744) in thal/R-
exposed, and 20.6 vs. 13.6 months (HR 0.700) in thal/R-
naïve patients. PFS was also prolonged with ixazomib-Rd
versus placebo-Rd in patients refractory to thalidomide
(HR 0.726; median PFS 16.6 vs. 13.0 months).
TTP was also longer with ixazomib-Rd than placebo-Rd
regardless of type of prior therapy received. When ana-
lyzed by prior PI exposure, median TTP with ixazomib-
Rd vs. placebo-Rd was 18.5 vs. 13.9 months (HR 0.702,
95% CI 0.526, 0.936) in PI-exposed patients, and not
estimable vs. 17.5 months (HR 0.741, 95% CI 0.456, 1.203)
in PI-naïve patients (Figure 3). For immunomodulatory
drug exposure, median TTP was not estimable vs. 18.3
months (HR 0.727, 95% CI 0.515, 1.026) in exposed
patients, and 20.6 vs. 13.6 months (HR 0.651, 95% CI
0.449, 0.945) in naïve patients.
Overall response rates (ORR) with ixazomib-Rd and
placebo-Rd appeared generally similar across most sub-
groups (PI-naïve: 81% vs. 74%; PI-exposed: 77% vs. 70%;
thal/R-naïve: 80% vs. 77%; R-naïve: 78% vs. 73%; Table
2) but were slightly lower in thalidomide-refractory
patients (70% vs. 57%). Complete response plus very
good partial response (CR+VGPR) rates with ixazomib-Rd
vs. placebo-Rd by patient subgroup are shown in Table 2;
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Figure 2. Kaplan-Meier analysis of progression-free survival (PFS) with ixazomib-Rd vs. placebo-Rd according to prior therapy. (A) PI-exposed patients; B) PI-naïve
patients; C) immunomodulatory drug-exposed patients; D) immunomodulatory drug-naïve patients; E) patients with 1 prior therapy; F) patients with 2/3 prior thera-
pies. CI: confidence interval; Rd: lenalidomide-dexamethasone.
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again, there was a consistent benefit with ixazomib-Rd
vs. placebo-Rd.
Efficacy according to number of prior therapies 
The benefit of ixazomib-Rd vs. placebo-Rd was seen
when assessed by number of prior therapies, with pro-
longed PFS and TTP and improved response rates seen
with ixazomib-Rd versus placebo-Rd in patients with 1
prior therapy and in those with 2 or 3 prior therapies
(Figures 1A and 2, Table 2). However, the benefit seemed
less pronounced in patients with 1 prior therapy versus
those with 2 or 3 prior therapies: the hazard ratio for PFS
was 0.88 (95% CI: 0.65–1.20) vs. 0.58 (95% CI: 0.40–0.84)
in patients with 1 vs. 2 or 3 prior therapies, respectively,
and the hazard ratio for TTP was 0.842 (95% CI 0.614,
1.156) vs. 0.550 (95% CI 0.370, 0.819) in patients with 1 vs.
2 or 3 prior therapies, respectively (Figures 1A and 3).      
To investigate this further, PFS was analyzed in patients
with 1 prior therapy and patients with 2 or 3 prior thera-
pies according to type of prior therapy received and other
clinical characteristics (Figure 1B). In patients with 2 or 3
prior therapies, the PFS benefit was consistent across all
subgroups, regardless of type of prior therapy received or
cytogenetic risk status. In patients with 1 prior therapy,
the magnitude of PFS benefit was consistent regardless of
prior exposure to PIs or immunomodulatory drugs (HR
~0.7 across all subgroups; Figure 1A), but was greater in
patients with high-risk cytogenetics (HR for PFS 0.64 
vs. 0.81 for those with standard-risk cytogenetics) and
those who did not have a prior transplant (HR for PFS 0.60
vs. 1.23 for those who did have a prior transplant) 
(Figure 1B). 
Safety
Of the 722 patients randomized, 720 received at least
one dose of study drug and were included in the safety
population (ixazomib-Rd N=361, placebo-Rd N=359). Per
the primary study report,20 safety data are reported from a
pre-specified analysis at a median follow up of approxi-
mately 23 months. Rates of all-grade AEs, grade ≥3 AEs,
and serious AEs for the overall population and by patient
subgroup are shown in Table 3. Rates of all-grade AEs,
Ixazomib-Rd in RRMM patients: impact of prior therapies
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Table 2. Response with ixazomib-Rd vs. placebo-Rd by type and number of prior therapies.
ORR ≥VGPR ≥CR
Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd
(N=360) (N=362) (N=360) (N=362)
Overall population 282 (78) 259 (72) 173 (48) 141 (39) 42 (12) 24 (7)
Prior PI Exposed 193/250 (77) 178/253 (70) 114/250 (46) 101/253 (40) 22/250 (9) 15/253 (6)
Naive 89/110 (81) 81/109 (74) 59/110 (54) 40/109 (37) 20/110 (18) 9/109 (8)
Prior immunomodulatory drug Exposed 149/193 (77) 137/204 (67) 87/193 (45) 71/204 (35) 22/193 (11) 13/204 (6)
Naïve 133/167 (80) 122/158 (77) 86/167 (51) 70/158 (44) 20/167 (12) 11/158 (7)
Prior thalidomide Exposed 122/157 (78) 114/170 (67) 73/157 (46) 58/170 (34) 20/157 (13) 10/170 (6)
Naïve 160/203 (79) 145/192 (76) 100/203 (49) 83/192 (43) 22/203 (11) 14/192 (7)
Prior lenalidomide Exposed 34/44 (77) 26/44 (59) 20/44 (45) 16/44 (36) 4/44 (9) 3/44 (7)
Naïve 248/316 (78) 233/318 (73) 153/316 (48) 125/318 (39) 38/316 (12) 21/318 (7)
Thalidomide-refractory Yes 28/40 (70) 28/49 (57) 12/40 (30) 13/49 (27) 2/40 (5) 2/49 (4)
No 254/320 (79) 231/313 (74) 161/320 (50) 128/313 (41) 40/320 (13) 22/313 (7)
Number of prior therapies 1 163/212 (77) 159/213 (75) 95/212 (45) 93/213 (44) 19/212 (9) 17/213 (8)
2 or 3 119/148 (80) 100/149 (67) 78/148 (53) 48/149 (32) 23/148 (16) 7/149 (5)
CR: complete response; ORR: overall response rate; PI: proteasome inhibitor; Rd: lenalidomide-dexamethasone; VGPR: very good partial response.
Table 3. Overall summary of adverse events (AEs) according to number and type of prior therapies. 
n / N (%) All-grade AEs Grade ≥3 AEs Serious AEs On-study deaths
Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd
Overall population 355/361 (98) 357/359 (99) 267/361 (74) 247/359 (69) 168/361 (47) 177/359 (49) 15/361 (4) 23/359 (6)
PI-naive 108/109 (99) 109/109 (100) 86/109 (79) 72/109 (66) 54/109 (50) 47/109 (43) 6/109 (6) 8/109 (7)
PI-exposed 247/252 (98) 248/250 (99) 181/252 (72) 175/250 (70) 114/252 (45) 130/250 (52) 9/252 (4) 15/250 (6)
Immuno-modulatory 161/166 (97) 156/158 (99) 125/166 (75) 112/158 (71) 80/166 (48) 80/158 (51) 8/166 (5) 12/158 (8)
drug-naive
Immuno-modulatory 194/195 (99) 201/201 (100) 142/195 (73) 135/201 (67) 88/195 (45) 97/201 (48) 7/195 (4) 11/201 (5)
drug-exposed
1 prior therapy 208/212 (98) 209/211 (99) 153/212 (72) 134/211 (64) 99/212 (47) 94/211 (45) 10/212 (5) 10/211 (5)
2-3 prior therapies 147/149 (99) 148/148 (100) 114/149 (77) 113/149 (76) 69/149 (46) 83/149 (56) 5/149 (3) 13/149 (9)
PI: proteasome inhibitor; Rd: lenalidomide-dexamethasone.   
grade ≥3 AEs, and serious AEs by patient subgroup were
largely consistent with those seen for the overall popula-
tion, the only exception being slightly higher rates of
grade ≥3 AEs and serious AEs with placebo-Rd in patients
with 2-3 prior therapies (76% and 56%, vs. 69% and 49%
in the overall population, respectively).
Rates of AEs of clinical interest, including neutropenia,
thrombocytopenia, peripheral neuropathy, rash, diarrhea,
nausea, and vomiting, are shown in Table 4; common
grade ≥3 AEs are shown in Online Supplementary Table S1.
Rates of AEs were largely consistent across patient sub-
groups (Online Supplementary Table S1). 
Across patient subgroups, the incidence of peripheral
neuropathy, a known side effect of the first-in-class PI
bortezomib, was largely consistent with the overall popu-
lation (27% vs. 22% for ixazomib-Rd vs. placebo-Rd),
including in PI-naïve (29% vs. 23%) and PI-exposed 
(26% vs. 21%) patients. Rates of grade ≥3 peripheral neu-
ropathy with ixazomib-Rd vs. placebo-Rd were also simi-
lar across patient subgroups: 3% vs. <1% of PI-naïve, 2%
vs. 2% of PI-exposed, 1% vs. 3% of immunomodulatory
drug-naïve, 4% vs. <1% of immunomodulatory drug-
exposed patients, 2% vs. 2% of patients with 1 prior ther-
apy, and 3% vs. 1% of patients with 2-3 prior therapies
(Online Supplementary Table S1). As with the overall popu-
lation, the incidence of cardiac, thromboembolism, and
renal failure toxicities were consistently low and similar in
both treatment groups regardless of prior therapy 
(Table 4).
Discussion
This subgroup analysis demonstrated that, as with the
overall TOURMALINE-MM1 study population,20 the
addition of ixazomib to Rd was associated with prolonged
PFS versus placebo-Rd across the patient subgroups ana-
lyzed, regardless of prior bortezomib or immunomodula-
tory drug exposure or number of prior therapies received.
This PFS benefit was accompanied by improved response
rates and a prolonged TTP versus placebo-Rd across all
prior therapy subgroups. Reflecting the findings in the
overall study population, the addition of ixazomib to
lenalidomide-dexamethasone was consistently associated
with limited additional toxicity regardless of prior therapy
subgroup.18 These efficacy and safety data are particularly
important given both the widespread use of PIs and
immunomodulatory drugs as front-line therapy in MM
and the relapsing nature of the disease.20 
Retreatment with bortezomib has previously been
shown to be feasible,14-17 as has the benefit of carfilzomib-
dexamethasone in patients with prior bortezomib expo-
sure.21 However, the median PFS with carfilzomib-dexam-
ethasone in bortezomib-exposed patients was less than
that in bortezomib-naïve patients (15.6 months vs. not
estimable), suggesting some effect of prior PI exposure on
the efficacy of carfilzomib-dexamethasone.21 In the pres-
ent study, ixazomib-Rd was associated with prolonged
PFS and TTP and improved response rates vs. placebo-Rd
in bortezomib-naïve and –exposed patients. Median PFS
with ixazomib-Rd appeared longer in bortezomib-naïve
vs. bortezomib-exposed patients (not estimable vs.18.5
months), but the associated hazard ratios vs. placebo-Rd
were similar (0.746 vs. 0.747), suggesting a similar PFS
benefit with ixazomib-Rd in bortezomib-naïve and 
-exposed patients. Although no conclusions can be drawn
regarding patients refractory to bortezomib, these similar
hazard ratios also suggest that the adverse impact of prior
bortezomib exposure on PFS and OS seen in a previous
study of Rd22 may not be the case when ixazomib is added
to the Rd regimen. 
The clinical benefit of ixazomib-Rd versus placebo-Rd
was also consistent regardless of prior exposure to
immunomodulatory drugs. Ixazomib-Rd was associated
with prolonged PFS vs. placebo-Rd in both immunomod-
ulatory drug-naïve and –exposed patients (with HR of
approximately 0.7 for both subgroups). Although only
12% of patients in each arm had received prior lenalido-
mide, ixazomib-Rd was associated with a clinical benefit
versus placebo-Rd in patients with prior lenalidomide
exposure (median PFS, not estimable vs. 17.5 months; HR
0.582), highlighting the benefit of adding a drug with a dif-
ferent mechanism of action for these patients. Of note, the
clinical benefit of ixazomib-Rd was also seen in thalido-
mide-refractory patients; as lenalidomide-refractory
patients were not eligible for the study, no conclusions can
be drawn regarding these patients. 
Patients with MM who have received multiple prior
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Figure 3. Forest plot of time to progression (TTP) according to number and type of prior therapies. CI: confidence interval; PI: proteasome inhibitor; Rd: lenalido-
mide-dexamethasone.
therapies are a particularly difficult-to-treat population,
with patient outcomes becoming progressively worse
with increasing prior therapies.6,9,20 This may be in part
due to clonal evolution, with multiple rounds of treatment
with different agents exerting selection pressure on
mutant plasma cells, leading to both the development of
increasingly treatment-resistant clones and the re-emer-
gence of original clones not completely suppressed.11 It is
therefore important that effective and tolerable treatments
are available for this heterogeneous patient population.
Importantly, ixazomib-Rd was associated with a particu-
lar clinical benefit vs. placebo-Rd in patients with multiple
prior therapies (HR 0.580; median PFS not estimable with
ixazomib-Rd vs. 12.9 months with placebo-Rd), and this
Ixazomib-Rd in RRMM patients: impact of prior therapies
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Table 4. Adverse events (AEs) of clinical interest according to number and type of prior therapies. 
Overall PI-naïve PI-exposed Immuno- Immuno- 1 prior 2-3 prior
population modulatory drug- modulatory drug- therapy therapies
naïve exposed
Common AEs of clinical interest
Neutropenia*
Ixazomib-Rd 118/361 (33) 39/109 (36) 79/252 (31) 52/166 (31) 66/195 (34) 62/212 (29) 41/149 (28)
Placebo-Rd 111/359 (31) 31/109 (28) 80/250 (32) 46/158 (29) 65/201 (32) 53/211 (25) 39/148 (26)
Thrombocytopenia†
Ixazomib-Rd 112/361 (31) 37/109 (34) 75/252 (30) 49/166 (30) 63/195 (32) 49/212 (23) 37/149 (25)
Placebo-Rd 57/359  (16) 13/109 (12) 44/250 (18) 31/158 (20) 26/201 (13) 21/211 (10) 20/148 (14)
Peripheral neuropathy‡
Ixazomib-Rd 97/361 (27) 32/109 (29) 65/252 (26) 40/166 (24) 57/195 (29) 61/212 (29) 36/149 (24)
Placebo-Rd 78/359 (22) 25/109 (23) 53/250 (21) 30/158 (19) 48/201 (24) 44/211 (21) 34/148 (23)
Diarrhea
Ixazomib-Rd 164/361 (45) 53/109 (49) 111/252 (44) 74/166 (45) 90/195 (46) 96/212 (45) 68/149 (46)
Placebo-Rd 139/359 (39) 47/109 (43) 92/250  (37) 56/158 (35) 83/201 (41) 92/211 (44) 47/148 (32)
Rash§
Ixazomib-Rd 72/361 (20) 25/109 (23) 47/252 (19) 33/166 (20) 39/195 (20) 34/212 (16) 38/149 (26)
Placebo-Rd 45/359 (13) 13/109 (12) 32/250 (13) 23/158 (15) 22/201 (11) 28/211 (13) 17/148 (11)
Nausea
Ixazomib-Rd 104/361 (29) 29/109 (27) 75/252 (30) 46/166 (28) 58/195 (30) 53/212 (25) 51/149 (34)
Placebo-Rd 79/359  (22) 24/109 (22) 55/250 (22) 29/158 (18) 50/201 (25) 45/211 (21) 34/148 (23)
Vomiting
Ixazomib-Rd 84/361 (23) 20/109 (18) 64/252 (25) 42/166 (25) 42/195 (22) 47/212 (22) 37/149 (25)
Placebo-Rd 42/359 (12) 12/109 (11) 30/250 (12) 20/158 (13) 22/201 (11) 21/211 (10) 21/148 (14)
Other AEs of clinical interest
Acute renal failure#
Ixazomib-Rd 31/361 (9) 9/109 (8) 22/252 (9) 17/166 (10) 14/195 (7) 5/212 (2) 4/149 (3)
Placebo-Rd 41/359 (11) 10/109 (9) 31/250 (12) 18/158 (11) 23/201 (11) 8/211 (4) 6/148 (4)
Venous embolic and thrombotic events#
Ixazomib-Rd 29/361 (8) 10/109 (9) 19/252 (8) 16/166 (10) 13/195 (7) 17/212 (8) 12/149 (8)
Placebo-Rd 38/359 (11) 11/109 (10) 27/250 (11) 19/158 (12) 19/201 (9) 22/211 (10) 16/148 (11)
Heart failure#
Ixazomib-Rd 16/361 (4) 8/109 (7) 8/252 (3) 7/166 (4) 9/195 (5) 12/212 (6) 4/149 (3)
Placebo-Rd 14/359 (4) 3/109 (3) 11/250(4) 6/158 (4) 8/201 (4) 7/211 (3) 7/148 (5)
Myocardial infarction#
Ixazomib-Rd 5/361 (1) 3/109 (3) 2/252 (<1) 1/166 (<1) 4/195 (2) 5/212 (2) 0
Placebo-Rd 8/359 (2) 3/109 (3) 5/250 (2) 4/158 (3) 4/201 (2) 3/211 (1) 5/211 (3)
*Data based upon standardized MedDRA query, including neutropenia and neutrophil count decreased. †Data based upon standardized MedDRA query, including thrombo-
cytopenia and platelet count decreased. ‡High-level term including peripheral neuropathy, peripheral sensory neuropathy, peripheral sensorimotor neuropathy, and peripheral
motor neuropathy. §High-level term including acute febrile neutrophilic dermatosis, acneiform dermatitis, allergic dermatitis, drug eruption, erythema multiforme, exfoliative
rash, interstitial granulomatous dermatitis, pruritus, generalised pruritus, purpura, rash, erythematous rash, follicular rash, generalised rash, macular rash, maculo-papular rash,
maculovesicular rash, morbilliform rash, papular rash, pruritic rash, pustular rash, vesicular rash, red man syndrome, Stevens-Johnson syndrome, Toxic epidermal necrolysis,
urticaria, urticarial papular, and vasculitic rash. #Data based upon standardized MedDRA query, incorporating pooled preferred terms, or multiple preferred terms. PI, protea-
some inhibitor; Rd, lenalidomide-dexamethasone.
was seen regardless of the type of prior therapies received.
While there was a clinical benefit with ixazomib-Rd vs.
placebo-Rd in patients with 1 prior therapy, the magni-
tude of benefit appeared reduced when compared to that
in patients with multiple prior therapies (HR vs. placebo-
Rd 0.88). These results appear to differ from those seen
with carfilzomib-Rd versus Rd alone, in which there was a
consistent benefit in patients with 1 prior therapy and in
those with ≥2 prior therapies (HR 0.694 and 0.688).23  The
further analysis of patients with 1 prior therapy in TOUR-
MALINE-MM1 suggests this difference may, in part, be
driven by effects in the subgroup of patients with prior
transplant (HR 1.232, vs. 0.604 in those with no prior
transplant). Across other subgroups of patients with 1
prior therapy there was a clear PFS benefit with ixazomib-
Rd vs. placebo-Rd, including those with high-risk cytoge-
netics. One possibility suggested by preliminary findings
is that tumors relapsed post-transplant  may have a dis-
tinct biology with a less differentiated phenotype and
lower expression of c-myc.24 The benefit (HR 0.44) in
patients with no prior transplant but prior melphalan-con-
taining therapy suggests that the difference is not due to
prior alkylator therapy but possibly due to the transplant
itself or, although speculative, due to the myeloablative
dose of melphalan administered before the transplant.
Several published data have previously suggested a link
between c-myc levels and the sensitivity to proteasome
inhibitors.25-27 Immunomodulatory drugs and proteasome
inhibitors appear to target different clones (less versus
more differentiated phenotypes, respectively), which
might explain in part their synergistic action and the
increased benefit observed with ixazomib-Rd.24 As the
study was not powered to detect a statistical difference
between the subgroups, and the transplant vs. non-trans-
plant analysis was retrospective and post-hoc rather than
a prespecified subgroup analysis, this finding is hypothe-
sis-generating and further investigations to characterize
the tumor biology are ongoing.24 
As seen in the overall population,18 the addition of ixa-
zomib was associated with limited additional toxicity
when compared with placebo-Rd across all patient sub-
groups. Overall, the safety profile of ixazomib-Rd was
similar regardless of number and type of prior therapies
and was consistent with that reported for the overall
patient population. Rates of all-grade AEs, grade ≥3 AEs
and SAEs were similar between subgroups and were
aligned with the rates seen in the overall study population.
Peripheral neuropathy and the hematologic AEs neutrope-
nia and thrombocytopenia are known side effects of PIs.
There were no consistent differences in all-grade or grade
≥3 AEs in patients with 1 vs. 2-3 prior therapies. This is in
contrast to results with carfilzomib-dexamethasone,
where rates of AEs were generally higher in patients with
2-3 prior therapies vs. 1 prior therapy.21 
There are a number of limitations associated with sub-
group analyses of this type. The subgroup analyses were
not powered for formal statistical testing, some were not
prespecified, and analyses did not use a multivariate
approach, hence there may be confounding factors, such
as an imbalance between some subgroups in terms of
other prognostic factors.
In conclusion, ixazomib plus lenalidomide-dexametha-
sone demonstrated a clear PFS, TTP, and response rate
benefit compared to lenalidomide-dexamethasone alone,
with limited additional toxicity, in patients with RRMM,
regardless of prior therapy received. The findings in
patients with 1 prior therapy and transplant are hypothe-
sis-generating and further investigations are ongoing.
Together, these findings support the results from the pri-
mary analysis of TOURMALINE-MM1, further demon-
strating that the all-oral regimen of ixazomib, lenalido-
mide, and dexamethasone represents an effective and tol-
erable treatment option for patients with RRMM.
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